In collaboration with four prestigious neurologists, Pivotal has begun screening patients for the Phase I research effort, which is expected to have major implications for the treatment of Alzheimer patients. The first patient is expected in-house early April 2008. The Phase I activity will continue through July 2008.
The study will involve 21 randomized patients who, under close protocol, will reside in Pivotal’s Phase I unit for the duration of 28 days. Pivotal Research Centers will utilize its trained and experienced Phase I staff to provide the expertise required for the compliance and success of the trial.
Bruce Shear, president and CEO of Pioneer, said: “This is the first big study since we opened our new Phase I expanded 15-bed unit this fiscal year. We anticipate this study to generate approximately $0.75 millions over the next four months and boost profits in the current quarter.”